DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025" report to their offering.
The non-small cell lung cancer (NSCLC) market across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan, and China, is set to rise from $6.21 billion in 2015 to $26.71 billion by 2025, representing a very strong compound annual growth rate of 15.7%.
The report states that the impressive strength of the market over the next decade can be attributed to the increasing incorporation of premium-priced immune checkpoint inhibitors into the NSCLC treatment algorithm, the launch of new targeted therapies, and the rising incidence of the disease across the 8MM.
In 2015, the NSCLC space was largely dominated by generic chemotherapy and targeted therapies, which accounted for around 94% of the market, while immuno-oncology sales accounted for just 6%. In 2025, that trend will be reversed, with 65% of the total NSCLC market going to immuno-oncology therapies, and the remaining 35% being split between chemotherapy and targeted agents.
A major trend in corporate strategy is the pairing of programmed cell death protein 1 (PD-1) checkpoint inhibitors with other agents. In the crowded PD-1 space, as drugs with identical mechanisms of action are launched, players are looking for ways to boost efficacy in hopes of differentiating their product from that of their competitors.
Companies such as Merck, Roche, and Bristol-Myers Squibb are evaluating their PD-1 checkpoint inhibitors in combination with chemotherapies, targeted agents, and/or other immuno-oncology products.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
5 Disease Management
6 Competitive Assessment
7 Unmet Needs Assessment and Opportunity Analysis
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
- Eli Lilly
- Bristol-Myers Squibb
- Merck & Co.
- Boehringer Ingelheim
For more information about this report visit http://www.researchandmarkets.com/research/pm545t/pharmapoint